Company Profile

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE935.857.85 (+0.85 % )
PREV CLOSE (Rs.) 928.00
OPEN PRICE (Rs.) 930.70
BID PRICE (QTY) 935.60 (18 )
OFFER PRICE (QTY) 936.20 (59 )
VOLUME 84685
TODAY'S LOW / HIGH (Rs.)925.20 945.45
52 WK LOW / HIGH (Rs.)505 955.85
NSE934.75 6.75 (+0.73 % )
PREV CLOSE(Rs.) 928.00
OPEN PRICE (Rs.) 932.80
BID PRICE (QTY) 934.75 (32 )
OFFER PRICE (QTY) 934.90 (6 )
VOLUME 2972665
TODAY'S LOW / HIGH(Rs.) 925.50 945.80
52 WK LOW / HIGH (Rs.)504.75 956

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.64
TTM EPS (Rs.) 16.06
P/E Ratio 58.28
Book Value (Rs.) 380.86
Face Value (Rs.) 2
MCap (Rs. in Mn) 424049.09
Price/Earning (TTM) 34.02
Price/Sales (TTM) 3.85
Price/Book (MRQ) 2.46
PAT Margin (%) 6.13
ROCE (%) 6.39
Incorporation Year : 1983

Management Info :

Manju D Gupta - Chairman Nilesh Gupta - Managing Director

Registered Office :

Address : Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone : 022 6640 2323

Website : www.lupinworld.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
05Aug08-05-2020$Lupin launches Favipiravir Drug Covihalt for treatment of mild to moderate COVID-19 Lupin launches Favipiravir D
Lupin has launched its Favipiravir Drug in India under the brand name Covihalt for the treatment of mild to moderate COVID-19. Favipiravir has received authorization from the Drug Controller General of India (DCGI) for emergency use.

Lupin’s Covihalt dosage strength has been developed keeping in mind convenience of administration. It is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs. 49 per tablet.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin has launched its Favipiravir Drug in India under the bran..
05Aug08-05-2020$TCS, Sun Pharmaceutical and NMDC to see some action today TCS, Sun Pharmaceutical and

Digitate, a software venture of Tata Consultancy Services (TCS) has launched ignio AI.Assurance, an autonomous assurance product that enables enterprises to deliver better software faster, enhancing their business performance. The new product enables development teams within enterprises to harness the power of artificial intelligence (AI) and machine learning to overcome the bottlenecks and deficiencies of their manual or assisted testing methods, and adopt cutting-edge quality engineering practices for timely software releases that help enterprises deliver unique and compelling customer experiences and enhance their competitive differentiation.

Sun Pharmaceutical Industries has launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

NMDC has recorded a sharp rise in overall production and sales in July 2020 as compared to the corresponding period in July 2019. During this period, despite the current uncertain situation due to COVID-19, the company has been able to achieve excellent physical performance through its continual push towards higher volumes which saw production of 2.19 million tones (MT) and sales 2.57 MT that grew by 13% and 7% over the corresponding period last year, respectively.

Power Finance Corporation (PFC) is targeting higher fund flow from 54EC capital gain bonds in the last two quarters of this fiscal and expects to register 25 percent growth in funds garnered from this instrument in 2020-21. The company had raised around Rs 1,100 crore from these bonds in 2019-20. However, despite getting good response in the last few years, the firm could not increase funding from this route in the first quarter of this fiscal mainly due to the COVID-19 impact.

Paushak has received approval to its application for amendment in Industrial License from the Department for Promotion of Industrial & Internal Trade, Ministry of Commerce & Industry vide its communication dated August 3, 2020 for expansion of licensed manufacturing capacity at its existing manufacturing facilities located at Panelav, Gujarat. With this approval, the company has announced expansion of licensed manufacturing capacity for the product Phosgene from 4,800 MT per annum to 14,400 MT per annum and graded capacity for its other phosgene based derivatives.

Indian Hotels Company (IHCL) has launched I-ZEST (Zero-Touch Service Transformation), a suite of digital solutions across its hotels under its brands -- Taj, Vivanta and SeleQtions. I-ZEST's digital features will further ensure social distancing for both guests and associates, while maintaining secure and seamless services. The digital initiatives come on the back of the company's foray into food delivery service from its iconic restaurants via a dedicated mobile app.

Lupin has received tentative approval for its Empagliflozin Tablets, 10 mg and 25 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Jardiance Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Digitate, a software venture of Tata Consultancy Services (TCS)..
04Aug08-04-2020$Lupin gets tentative approval for Empagliflozin tablets Lupin gets tentative approva
Lupin has received tentative approval for its Empagliflozin Tablets, 10 mg and 25 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Jardiance Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin Tablets, 10 mg and 25 mg (RLD: Jardiance) had an annual sales of approximately $4,368 million in the U.S. (IQVIA MAT Mar 2020).  

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin has received tentative approval for its Empagliflozin Tab..
04Aug08-04-2020$Lupin rises on getting tentative approval for Empagliflozin tablets Lupin rises on getting tenta

Lupin is currently trading at Rs. 935.80, up by 8.80 points or 0.95% from its previous closing of Rs. 927.00 on the BSE.

The scrip opened at Rs. 930.00 and has touched a high and low of Rs. 942.95 and Rs. 912.00 respectively. So far 115893 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 955.85 on 15-Jun-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 946.30 and Rs. 843.70 respectively. The current market cap of the company is Rs. 42441.16 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.88% and 12.91% respectively.

Lupin has received tentative approval for its Empagliflozin Tablets, 10 mg and 25 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Jardiance Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin Tablets, 10 mg and 25 mg (RLD: Jardiance) had an annual sales of approximately $4,368 million in the U.S. (IQVIA MAT Mar 2020). 

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

 

Lupin is currently trading at Rs. 935.80, up by 8.80 points or..
24Jul07-24-2020$Lupin gets USFDA’s tentative nod for Empagliflozin, Linagliptin Tablets Lupin gets USFDA’s tentati

Lupin has received tentative approval for its Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Glyxambi Tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin and Linagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg (RLD: Glyxambi) had an annual sales of approximately $242 million in the U.S. (IQVIA MAT Mar 2020).

Lupin is an innovation led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin has received tentative approval for its Empagliflozin and..
Financials More
Rs. in Millions
QTR Mar 20 ANNUAL 20
Net Profit2252.97275.5
Gross Profit 3091.6 10522.5
Operating Profit 4453.223828
Net Sales 24838.8110256.6
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Aarti Drugs (BSE)
 2145.35 (13.97%)
M.Cap ( in Cr)
4860.38
Valiant Organics (BSE)
 2350.05 (8.55%)
M.Cap ( in Cr)
2806.47
Torrent Pharma (BSE)
 2976.35 (4.05%)
M.Cap ( in Cr)
50050.25
Alembic Pharma (BSE)
 1080.75 (7.52%)
M.Cap ( in Cr)
19886.54
Divis Lab (BSE)
 2735.60 (2.60%)
M.Cap ( in Cr)
72526.02
Shareholding Pattern More
FI/BANKS/INSURANCE 6.56 %
PROMOTERS 46.92 %
NON-INSTITUTION 12.91 %
MUTUAL FUNDS/UTI 11.94 %
GOVERNMENT 0.29 %
FII 0 %
F & O Quotes